KRN7000
Phase 1/2Completed 1 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Chronic Hepatitis C
Conditions
Chronic Hepatitis C
Trial Timeline
Aug 1, 2003 → May 1, 2005
NCT ID
NCT00352235About KRN7000
KRN7000 is a phase 1/2 stage product being developed by Kyowa Kirin for Chronic Hepatitis C. The current trial status is completed. This product is registered under clinical trial identifier NCT00352235. Target conditions include Chronic Hepatitis C.
What happened to similar drugs?
20 of 20 similar drugs in Chronic Hepatitis C were approved
Approved (20) Terminated (3) Active (0)
Hype Score Breakdown
Clinical
9
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00352235 | Phase 1/2 | Completed |
Competing Products
20 competing products in Chronic Hepatitis C
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Levofloxacin 500 | Dr. Reddy's Laboratories | Pre-clinical | 23 |
| mRNA-0184 | Moderna | Phase 1 | 0 |
| Lubiprostone + Lubiprostone + Placebo | Dr. Reddy's Laboratories | Phase 3 | 37 |
| macitentan 10 mg | BML, Inc. | Phase 3 | 32 |
| KPL-716 + Placebo | Kiniksa Pharmaceuticals | Phase 2 | 29 |
| TERN-701 | Terns Pharmaceuticals | Phase 1/2 | 36 |
| Fludarabine + Cyclophosphamide + PRGN-3007 | Precigen | Phase 1 | 23 |
| LY3556050 + Placebo | Eli Lilly | Phase 2 | 35 |
| THB001 | Third Harmonic Bio | Phase 1 | 11 |
| Briquilimab | Jasper Therapeutics | Phase 1/2 | 26 |
| Briquilimab | Jasper Therapeutics | Phase 1/2 | 14 |
| Briquilimab | Jasper Therapeutics | Phase 2 | 29 |
| Empagliflozin + Matching placebo | Eli Lilly | Phase 3 | 40 |
| LY3461767 + Placebo | Eli Lilly | Phase 1 | 29 |
| Pirtobrutinib + Venetoclax + Rituximab | Eli Lilly | Phase 3 | 44 |
| LY3526318 + Placebo | Eli Lilly | Phase 2 | 35 |
| Pirtobrutinib | Eli Lilly | Phase 2 | 42 |
| Ibrutinib + LY3214996 | Eli Lilly | Phase 1 | 21 |
| Pirtobrutinib + Acalabrutinib | Eli Lilly | Phase 2 | 27 |
| LYR-210 | Lyra Therapeutics | Phase 2 | 25 |